Intellia Therapeutics (NTLA) Price & Analysis

Compare

3,678 Followers

NTLA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.90 - $27.28

Previous CloseN/A

Volume723.92K

Average Volume (3M)4.71M

Market Cap

$1.36B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta2.47

Next Earnings

Jul 31, 2025

EPS Estimate

-1.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.10

Shares Outstanding103,583,400

10 Day Avg. Volume4,817,445

30 Day Avg. Volume4,706,848

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$29.88

Price Target Upside139.04% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering21

Bulls Say, Bears Say

Bulls Say

Clinical ProgressThe Phase 3 HAELO study, evaluating 50mg lonvo-z, has completed screening ahead of schedule, indicating strong progress in the program.

EfficacyLonvo-z achieved 100% HAE attack elimination in 12 months of additional Phase I follow-up, pointing to a high likelihood of Phase III success and an attractive commercial profile.

SafetyThe updated safety profile for lonvo-z was consistent with previous results, showing no serious adverse events and manageable infusion-related reactions.

Bears Say

Clinical UncertaintyThe potential for a larger sample size in Phase II to lead to an inferior effect compared to Phase I results suggests uncertainty in replicating earlier success.

Market ExpectationsThe valuation disconnect between the HAE opportunity and NTLA’s market cap is one of the widest, which may persist until NTLA releases pivotal HAE data or addresses investor concerns on the balance sheet.

Market OpportunityThe HAE market and available treatments limit Lonvo-z opportunity size, suggesting limited uptake.

Intellia Therapeutics News

Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for ATTRv-PN

Regeneron Pharmaceuticals (($REGN)), Intellia Therapeutics Inc (($NTLA)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals and...

6h ago

NTLA

REGN

Regeneron and Intellia’s Promising Phase 3 Study on NTLA-2001 for ATTR-CM

Regeneron Pharmaceuticals (($REGN)), Intellia Therapeutics Inc (($NTLA)) announced an update on their ongoing clinical study. The recent clinical...

6h ago

NTLA

REGN

Insider Sales Shake Up Southern Co, Constellation, Intellia, US Bancorp, and Kohl’s

Insiders have been trading these 5 stocks: (($SO)), (($STZ)), (($NTLA)), (($USB)) and (($KSS)). Here is a breakdown of...

4d ago

KSS

Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B

Regeneron Pharmaceuticals (($REGN)), Intellia Therapeutics Inc (($NTLA)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals and...

6d ago

NTLA

REGN

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer?

Regeneron Pharmaceuticals (($REGN)), Intellia Therapeutics Inc (($NTLA)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals and...

13d ago

NTLA

REGN

Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B

Regeneron Pharmaceuticals (($REGN)), Intellia Therapeutics Inc (($NTLA)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals and...

15d ago

NTLA

REGN

Insider Sales Shake Royal Caribbean, Kroger, HP, Intellia, EOG

Insiders have been trading these 5 stocks: (($RCL)), (($KR)), (($HPE)), (($NTLA)) and (($EOG)). Here is a breakdown of...

25d ago

EOG

Promising Phase 1 Results and High Interest in Phase 3 Trial Boost Buy Rating for Intellia Therapeutics

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on NTLA stock, giving a Buy rating yesterday....

1M ago

NTLA

Intellia Therapeutics Announces Positive Phase 1 Trial Data

Intellia Therapeutics ( ($NTLA) ) has issued an update. On June 15, 2025, Intellia Therapeutics announced positive three-year...

1M ago

NTLA

Intellia Therapeutics’ Lonvo-z Shows Promising Efficacy and Safety, Supporting Buy Rating

Intellia Therapeutics (NTLA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday....

1M ago

NTLA

Intellia Therapeutics price target lowered to $54 from $74 at Canaccord

Canaccord lowered the firm’s price target on Intellia Therapeutics (NTLA) to $54 from $74 and keeps a Buy...

2M ago

NTLA

Cathie Wood’s ARK Investment buys 226K shares of Intellia Therapeutics today

23:28 EDT Cathie Wood’s ARK Investment buys 226K shares of Intellia Therapeutics (NTLA) today Published first on TheFly...

2M ago

NTLA

Cathie Wood’s ARK Investment buys 201K shares of Intellia Therapeutics today

20:49 EDT Cathie Wood’s ARK Investment buys 201K shares of Intellia Therapeutics (NTLA) today Published first on TheFly...

2M ago

NTLA

Court blocks Trump tariffs, Musk steps away from DOGE: Morning Buzz

The major averages were broadly higher in the early going on the back of Nvidia’s post-earnings rally and...

2M ago

NTLA FAQ

What was Intellia Therapeutics’s price range in the past 12 months?

Intellia Therapeutics lowest stock price was $5.90 and its highest was $27.27 in the past 12 months.

What is Intellia Therapeutics’s market cap?

Intellia Therapeutics’s market cap is $1.36B.

When is Intellia Therapeutics’s upcoming earnings report date?

Intellia Therapeutics’s upcoming earnings report date is Jul 31, 2025 which is tomorrow.

How were Intellia Therapeutics’s earnings last quarter?

Intellia Therapeutics released its earnings results on May 08, 2025. The company reported -$1.1 earnings per share for the quarter, beating the consensus estimate of -$1.279 by $0.179.

Is Intellia Therapeutics overvalued?

According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Intellia Therapeutics pay dividends?

Intellia Therapeutics does not currently pay dividends.

What is Intellia Therapeutics’s EPS estimate?

Intellia Therapeutics’s EPS estimate is -1.02.

How many shares outstanding does Intellia Therapeutics have?

Intellia Therapeutics has 103,583,400 shares outstanding.

What happened to Intellia Therapeutics’s price movement after its last earnings report?

Intellia Therapeutics reported an EPS of -$1.1 in its last earnings report, beating expectations of -$1.279. Following the earnings report the stock price went up 13.58%.

Which hedge fund is a major shareholder of Intellia Therapeutics?

Currently, no hedge funds are holding shares in NTLA

Intellia Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-57.92%

Trailing 12-Months

Asset Growth

-21.71%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Intellia Therapeutics

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics (NTLA) Earnings & Revenues

NTLA Earnings Data >

NTLA Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Intellia Therapeutics showed strong progress in its clinical pipeline with advancements in Phase 3 studies and key regulatory milestones. Financially, the company maintains a robust position despite some short-term revenue declines and restructuring costs, which are expected to bring future savings. The overall sentiment is positive, driven by significant clinical and regulatory advancements outweighing the financial challenges.Read More>

NTLA Revenue Breakdown

100.00% Collaboration revenue

NTLA Stock 12 Month Forecast

Average Price Target

$29.88

▲(139.04%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","66":"$66","20.25":"$20.3","35.5":"$35.5","50.75":"$50.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,20.25,35.5,50.75,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.88,14.120000000000001,18.36,22.6,26.840000000000003,31.080000000000005,35.32,39.56,43.800000000000004,48.040000000000006,52.28000000000001,56.52,60.760000000000005,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.88,11.418461538461539,12.956923076923077,14.495384615384616,16.033846153846156,17.572307692307692,19.110769230769233,20.64923076923077,22.18769230769231,23.72615384615385,25.264615384615386,26.803076923076922,28.341538461538462,{"y":29.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.88,9.65846153846154,9.436923076923078,9.215384615384616,8.993846153846155,8.772307692307693,8.55076923076923,8.329230769230769,8.107692307692307,7.886153846153846,7.664615384615384,7.443076923076923,7.2215384615384615,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.38,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.47,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.14,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.2,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.81,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.32,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >